Alzheimer’s Disease, the Four Horsemen, and What the AMBAR Trial Actually Found

A person begins repeating a question they answered an hour ago. Managing familiar bills becomes difficult. A family member notices a change in judgment, language, or personality. What begins as a concern about memory can gradually alter a person’s independence and the lives of everyone who cares for them.

Alzheimer’s disease is a progressive brain disease and the most common cause of dementia. It affects networks involved in memory, thinking, behavior, and eventually the ability to manage everyday activities. Changes associated with the disease include the accumulation of amyloid-beta plaques and tau tangles, along with damage to and loss of brain cells. Alzheimer’s is not simply “normal aging,” and its impact extends well beyond forgetfulness.

The scale is substantial. The Alzheimer’s Association estimates that 7.4 million Americans age 65 and older were living with Alzheimer’s in 2026, or approximately one in nine people in that age group. Nearly 13 million Americans provide unpaid care for someone with Alzheimer’s or another dementia. The Association projects $409 billion in U.S. health and long-term care costs for people living with dementia in 2026, before accounting for the value of unpaid caregiving.

These numbers describe patients, spouses, children, and families navigating a disease that can unfold over years. They are part of why brain health belongs at the center of a serious longevity conversation.

The Institute’s philosophy: address the major threats before they take more away

At the Institute for Human Optimization, we often organize our thinking around four broad threats to long-term health: cardiovascular disease, cancer, neurodegenerative disease, and metabolic dysfunction. This is commonly referred to as Four Horsemen. They are a framework for asking better questions, not a prediction of any individual person’s future. These categories overlap; metabolic dysfunction, for example, can contribute to cardiovascular risk.

Our aim is straightforward :prevent the preventable, reverse the reversible, and delay the inevitable.

In brain health, that means taking modifiable risks seriously, investigating changes rather than dismissing them, and identifying treatable conditions that can affect cognition. It also means being honest about the limits of medicine. Addressing a reversible contributor to cognitive symptoms is not the same as reversing Alzheimer’s disease.

When someone already has a diagnosis or is worried that one may be developing the question becomes more urgent: What is supported by evidence today, and what is still being investigated?

Why researchers studied plasma exchange in Alzheimer’s disease

The AMBAR trial investigated one emerging approach: plasma exchange with albumin replacement. Therapeutic plasma exchange, or TPE, removes a portion of a person’s plasma and returns their blood cells with replacement fluid. AMBAR researchers studied whether a structured exchange regimen might affect decline in people with mild-to-moderate Alzheimer’s disease.

The trial enrolled 347 participants and compared treatment groups with a sham-procedure group over approximately 14 months. Treatment involved an initial period of weekly conventional plasma exchange followed by monthly lower-volume exchanges. Some groups also received intravenous immunoglobulin. This was a specific, prolonged research protocol not evidence that an occasional TPE session has the same effect.

At the end of the study, the combined treatment groups showed less decline in activities of daily living than the sham group; that difference met the study’s threshold for statistical significance. A co-primary measure of cognition favored treatment but did not meet the conventional threshold for statistical significance in the overall study population. Results also varied by disease severity: the researchers reported more encouraging findings in the moderate-Alzheimer’s subgroup, while the mild-Alzheimer’s subgroup did not show the same benefit.

AMBAR is an important study. It is not proof that TPE prevents, reverses, or cures Alzheimer’s disease, and further research is needed to determine whether and for whom its findings can be reproduced.

Safety belongs in that discussion, too. Plasma exchange is an invasive medical procedure with potential complications; adverse events were more common among AMBAR participants receiving treatment than among those receiving the sham procedure. Promising research does not remove the need to weigh those risks against uncertain benefits for an individual patient.

Research participation and individual care are different paths

The Institute for Human Optimization participates in clinical research related to Alzheimer’s disease. Clinical research has its own oversight, eligibility requirements, consent process, and investigational interventions. It is separate from the clinical services we may consider for individual patients.

We may also evaluate whether TPE is appropriate for a selected individual. That decision begins with a physician-led review of their diagnosis, medical history, goals, relevant testing, available alternatives, and procedural risks. An evaluation is not a commitment to treatment. In some cases, the most responsible recommendation will be not to proceed with TPE.

Families facing Alzheimer’s deserve more than either false certainty or a dismissal of emerging science. They deserve a careful account of what a study found, what it did not find, and how that evidence applies or does not apply to the person in front of us.

If you would like to discuss brain health, Alzheimer’s research, or whether an individualized TPE evaluation is appropriate, contact the Institute for Human Optimization. An inquiry does not establish clinical-trial eligibility or suitability for TPE.

This article is educational and does not replace individual medical advice. TPE is not an established treatment to prevent, reverse, or cure Alzheimer’s disease. Research participation and clinical treatment require separate evaluation and informed consent.

Sources :Alzheimer’s Association, 2026 Alzheimer’s Disease Facts and Figures;Boada M, et al., primary results of the AMBAR trial,Alzheimer’s & Dementia(2020).